Opportunity Information: Apply for PA 19 034
This NIH funding opportunity (PA-19-034) supports Small Business Innovation Research and Small Business Technology Transfer-style projects (R43/R44 mechanisms) aimed at turning "understudied" proteins from the Illuminating the Druggable Genome (IDG) initiative into commercially useful scientific products and, ultimately, drug discovery starting points. IDG is a Common Fund effort designed to figure out what selected, poorly characterized proteins in the druggable genome do and how they might be targeted, with an emphasis on expanding the set of proteins that can realistically be pursued by the biomedical community. The FOA is structured to pull small businesses into that ecosystem so they can take IDG-generated knowledge, tools, and targets and push them toward real-world adoption and market readiness.
The core idea is that IDG has built a consortium that generates and organizes resources, but small companies are often better positioned to package those resources into scalable, validated offerings that other labs and drug developers can use. IDG includes Data and Resource Generation Centers (DRGCs) that create datasets and reagents, a Knowledge Management Center (KMC) that organizes and integrates information, a Resource Dissemination and Outreach Center (RDOC) that helps get tools into users hands, and efforts developing Cutting Edge Informatics Tools (CEITs). Applicants are expected to complement these centers by taking IDG-related outputs (or approaches aligned with IDG priorities) and performing the practical validation and productization work needed for commercialization.
Projects can span a range of early-stage translation activities. On the lighter end, an application might focus on proof-of-concept demonstrations that show a particular understudied protein can be interrogated in a reliable way, or that a new tool meaningfully improves the ability to study that protein. On the more development-oriented end, proposals can include assay development and assay validation work that makes a target more tractable for screening and lead discovery. The FOA also allows projects that begin to initiate preclinical drug discovery efforts, as long as they remain within the intended scope for early research and commercialization planning. Across these possibilities, the unifying theme is to reduce the practical barriers that keep understudied proteins out of mainstream biology and drug development pipelines, and to do so in a way that leads to a product, service, or platform a small business can realistically bring to market.
The funding instrument is a discretionary NIH grant using the R43/R44 SBIR framework, and it explicitly states that clinical trials are not allowed under this announcement. The eligible applicant pool is limited to small business concerns, and the opportunity is not open to non-U.S. (foreign) institutions. In addition, non-domestic components of U.S. organizations are not eligible to apply, although foreign components may be permitted in limited cases consistent with NIH policy definitions and approvals. The opportunity sits within NIH health-related program areas and is tied to multiple CFDA listings, reflecting its cross-cutting relevance to different NIH institutes and centers that have an interest in improving the druggability and functional understanding of neglected protein targets.
In practical terms, a strong application under this FOA would typically make a clear case for why a specific understudied protein (or class of proteins) matters, what IDG-linked gap is being addressed, and how the proposed work will produce a validated, adoptable output. That could be a high-quality reagent with demonstrated performance, a standardized assay with reproducibility data, a dataset packaged for broad use, or an informatics tool that makes IDG knowledge easier to apply in real workflows. Just as important, the proposal would be expected to connect the technical plan to a credible commercialization path, showing that the end result is not just another academic prototype but something that can be manufactured, supported, distributed, and used by customers in biomedical research or early drug discovery.Apply for PA 19 034
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.242, 93.350, 93.393, 93.394, 93.395, 93.396, 93.399, 93.879.
- This funding opportunity was created on 2018-10-24.
- Applicants must submit their applications by 2021-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Education, Health
Next opportunity: Public Humanities Projects
Previous opportunity: Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (U01) (Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 19 034
Applicants also applied for:
Applicants who have applied for this opportunity (PA 19 034) also looked into and applied for these:
| Funding Opportunity |
|---|
| Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed) Apply for PA 19 033 Funding Number: PA 19 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Promoting Research on Music and Health: Fundamentals and Applications (R01 Clinical Trials Optional) Apply for RFA NS 19 008 Funding Number: RFA NS 19 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional) Apply for PAR 19 045 Funding Number: PAR 19 045 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21- Clinical Trial Optional) Apply for PAR 19 044 Funding Number: PAR 19 044 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3 Clinical Trial Required) Apply for RFA CA 19 018 Funding Number: RFA CA 19 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional) Apply for PAR 19 058 Funding Number: PAR 19 058 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional) Apply for PAR 19 057 Funding Number: PAR 19 057 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NINR Clinical Trial Planning Grant (R34 Clinical Trial Required) Apply for PAR 19 060 Funding Number: PAR 19 060 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) Apply for PAR 19 064 Funding Number: PAR 19 064 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Implementation Science for Cancer Control: Advanced Centers (P50 Clinical Trial Optional) Apply for RFA CA 19 006 Funding Number: RFA CA 19 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,200,000 |
| Implementation Science for Cancer Control: Developing Centers (P50 Clinical Trial Optional) Apply for RFA CA 19 005 Funding Number: RFA CA 19 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional) Apply for PA 19 074 Funding Number: PA 19 074 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Data Science Research: Personal Health Libraries for Consumers and Patients (R01 Clinical Trial Optional) Apply for PAR 19 072 Funding Number: PAR 19 072 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional) Apply for PA 19 073 Funding Number: PA 19 073 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Independent Scientist Award (Parent K02 - Independent Basic Experimental Studies with Humans Required) Apply for PA 19 085 Funding Number: PA 19 085 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional) Apply for PAR 19 093 Funding Number: PAR 19 093 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional) Apply for RFA DA 19 019 Funding Number: RFA DA 19 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 - Clinical Trial Optional) Apply for RFA DA 19 020 Funding Number: RFA DA 19 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional) Apply for RFA DA 19 025 Funding Number: RFA DA 19 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| HEAL Initiative Limited Competition: Behavioral Research to Improve MAT: Ancillary Studies to Enhance Behavioral or Social Interventions to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders (R01, Clinical Trials Optional) Apply for RFA AT 19 007 Funding Number: RFA AT 19 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 19 034", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.